

- **Name:** Alan Ashworth
  - **Current Position & Affiliation:** President of the Helen Diller Family Comprehensive Cancer Center at University of California, San Francisco and Senior Vice President for clinical services, UCSF Health
  - **Country:** USA
- 

• **Educational Background:** BSc Imperial College, London; PhD University College, London.

• **Professional Experience:** Former CEO, Institute of Cancer Research, London

• **Professional Organizations:** Member of the European Molecular Biology Organization (EMBO) and a Fellow of the Academy of Medical Sciences, the American Association of Arts and Sciences, the American Association of Cancer Research and the Royal Society.

• **Main Scientific Publications:**

Turner, N., Tutt, A. and Ashworth, A. (2004) Hallmarks of 'BRCAness' in sporadic cancers. *Nat Rev Cancer*, **4**, 814-819.

Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson, T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., Martin, N.M., Jackson, S.P., Smith, G.C. and Ashworth, A. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature*, **434**, 917-921.

Edwards, S.L., Brough, R., Lord, C.J., Natrajan, R., Vatcheva, R., Levine, D.A., Boyd, J., Reis-Filho, J.S. and Ashworth, A. (2008) Resistance to therapy caused by intragenic deletion in BRCA2. *Nature*, **451**, 1111-1115.

Ashworth, A., Lord, C. J. and Reis-Filho, J. S. (2011) Genetic Interactions in Cancer Progression and Treatment. *Cell* **145**, 30 - 38.

Lord, C.J., Ashworth, A., (2017). PARP inhibitors: Synthetic lethality in the clinic. *Science* **355**, 1152–1158.

Shifrut E., Carnevale J., Tobin V., Roth T.L., Woo J.M., Bui C.T., Li P.J., Diolaiti M.E., Ashworth A., Marson A., (2018). Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function. *Cell*. **175** 7, 1958-1971 e1915.